We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Low Volumes Mar Kansas City Southern (KSU) Q4 Earnings?
Read MoreHide Full Article
Kansas City Southern is scheduled to report fourth-quarter 2019 earnings numbers on Jan 17, before the market opens.
The Zacks Consensus Estimate for the company’s fourth-quarter earnings has been revised downward by 3 cents in the past 60 days.
Let’s unearth the factors that might have induced this bleak prediction.
Persistent sluggishness in freight volumes is likely to have affected the company’s top line in the fourth quarter. Volume softness at key divisions might get reflected in overall volumes. While weakness in the U.S. market is expected to have hurt intermodal volumes, unscheduled plant shutdown might have weighed on automotive volumes. Meanwhile, volumes at the Energy segment might have taken a hit due to weaknesses in the crude oil and frac sand sub-groups.
The Zacks Consensus Estimate for intermodal volumes suggests a 5.2% decline from the year-ago reported number. The same for automotive volumes indicates a 3.5% dip from that reported in the fourth quarter of 2018.
However, improved operational efficiency, courtesy of the precision scheduled railroading model, is expected to have driven earnings in the soon-to-be-reported quarter. This apart, the bottom line is expected to have been boosted by the company’s cost-cutting measures. Cost-reduction efforts are also likely to get reflected in the company’s operating ratio (operating expenses as a percentage of revenues).
The Zacks Consensus Estimate for the company’s operating ratio implies a 100-basis point improvement from the year-ago reported figure.
The proven Zacks model does not conclusively predict an earnings beat for Kansas City Southern in the fourth quarter of 2019. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Kansas City Southern has an Earnings ESP of -0.65% as the Most Accurate Estimate is pegged at $1.8, lower than the Zacks Consensus Estimate of $1.81. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Kansas City Southern carries a Zacks Rank #3.
Highlights of Q3 Earnings
In the last reported quarter, the company delivered a positive earnings surprise of 9.6%. The bottom line also improved 23.6% year over year on the back of better operational performance. Meanwhile, total revenues increased 7% year over year, surpassing the Zacks Consensus Estimate.
Stocks to Consider
Investors interested in the broader Transportation sector may consider Azul S.A. (AZUL - Free Report) , Copa Holdings, S.A. (CPA - Free Report) and Canadian Pacific Railway Limited (CP - Free Report) as these stocks possess the right combination of elements to come up with an earnings beat in their next releases.
Azul has an Earnings ESP of +13.33% and a Zacks Rank of 1.
Copa Holdings is a #3 Ranked stock and has an Earnings ESP of +3.33%.
Canadian Pacific has an Earnings ESP of +0.16% and a Zacks Rank of 3. The company will release fourth-quarter 2019 earnings numbers on Jan 29.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Low Volumes Mar Kansas City Southern (KSU) Q4 Earnings?
Kansas City Southern is scheduled to report fourth-quarter 2019 earnings numbers on Jan 17, before the market opens.
The Zacks Consensus Estimate for the company’s fourth-quarter earnings has been revised downward by 3 cents in the past 60 days.
Let’s unearth the factors that might have induced this bleak prediction.
Persistent sluggishness in freight volumes is likely to have affected the company’s top line in the fourth quarter. Volume softness at key divisions might get reflected in overall volumes. While weakness in the U.S. market is expected to have hurt intermodal volumes, unscheduled plant shutdown might have weighed on automotive volumes. Meanwhile, volumes at the Energy segment might have taken a hit due to weaknesses in the crude oil and frac sand sub-groups.
The Zacks Consensus Estimate for intermodal volumes suggests a 5.2% decline from the year-ago reported number. The same for automotive volumes indicates a 3.5% dip from that reported in the fourth quarter of 2018.
However, improved operational efficiency, courtesy of the precision scheduled railroading model, is expected to have driven earnings in the soon-to-be-reported quarter. This apart, the bottom line is expected to have been boosted by the company’s cost-cutting measures. Cost-reduction efforts are also likely to get reflected in the company’s operating ratio (operating expenses as a percentage of revenues).
The Zacks Consensus Estimate for the company’s operating ratio implies a 100-basis point improvement from the year-ago reported figure.
Kansas City Southern Price and EPS Surprise
Kansas City Southern price-eps-surprise | Kansas City Southern Quote
Earnings Whispers
The proven Zacks model does not conclusively predict an earnings beat for Kansas City Southern in the fourth quarter of 2019. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as elaborated below. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Kansas City Southern has an Earnings ESP of -0.65% as the Most Accurate Estimate is pegged at $1.8, lower than the Zacks Consensus Estimate of $1.81. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Kansas City Southern carries a Zacks Rank #3.
Highlights of Q3 Earnings
In the last reported quarter, the company delivered a positive earnings surprise of 9.6%. The bottom line also improved 23.6% year over year on the back of better operational performance. Meanwhile, total revenues increased 7% year over year, surpassing the Zacks Consensus Estimate.
Stocks to Consider
Investors interested in the broader Transportation sector may consider Azul S.A. (AZUL - Free Report) , Copa Holdings, S.A. (CPA - Free Report) and Canadian Pacific Railway Limited (CP - Free Report) as these stocks possess the right combination of elements to come up with an earnings beat in their next releases.
Azul has an Earnings ESP of +13.33% and a Zacks Rank of 1.
Copa Holdings is a #3 Ranked stock and has an Earnings ESP of +3.33%.
Canadian Pacific has an Earnings ESP of +0.16% and a Zacks Rank of 3. The company will release fourth-quarter 2019 earnings numbers on Jan 29.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>